Shares of AnaptysBio Inc. (ANAB) are down over 50% from their 52-week high of $41.31, recorded last August, with the stock now hovering around the $20 level.
This clinical-stage biotechnology company is developing immunology therapeutics for autoimmune and inflammatory diseases. Its lead drug candidate is Rosnilimab, which is in a phase IIb trial for the treatment of rheumatoid arthritis and in a phase II trial for the treatment of ulcerative colitis.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.